Showing results (101-110 of 155) with videos related to

Sort By:
Pageof 16
Antimicrobial Agents and Chemotherapy|November 14, 2012
Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearanceJürgen B Bulitta, Olanrewaju O Okusanya, Alan Forrest, et al.
Antimicrobial Agents and Chemotherapy|September 27, 2017
Pharmacokinetics-Pharmacodynamics of CB-618 in Combination with Cefepime, Ceftazidime, Ceftolozane, or Meropenem: the Pharmacological Basis for a Stand-Alone β-Lactamase InhibitorPaul G Ambrose, Brian D VanScoy, Michael Trang, et al.
Diagnostic Microbiology and Infectious Disease|April 26, 2011
Evaluation of the pharmacokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selectionOlanrewaju O Okusanya, Brian T Tsuji, Jurgen B Bülitta, et al.
Antimicrobial Agents and Chemotherapy|December 7, 2011
Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecyclineSujata M Bhavnani, Christopher M Rubino, Jeffrey P Hammel, et al.
Journal of Clinical Pharmacology|August 3, 2013
Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumoniaScott A Van Wart, Alan Forrest, Tatiana Khariton, et al.
Diagnostic Microbiology and Infectious Disease|January 20, 2009
Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococciPaul G Ambrose, Alison K Meagher, Julie A Passarell, et al.
Diagnostic Microbiology and Infectious Disease|August 26, 2006
Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic modelPatrick F Smith, Brian Tsuji, Brent M Booker, et al.
Antimicrobial Agents and Chemotherapy|January 24, 2019
Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical StudiesMichael Trang, Julie D Seroogy, Scott A Van Wart, et al.
Antimicrobial Agents and Chemotherapy|July 15, 2020
Relationship between Gepotidacin Exposure and Prevention of On-Therapy Resistance Amplification in a Neisseria gonorrhoeae Hollow-Fiber In Vitro Infection ModelBrian D VanScoy, Nicole E Scangarella-Oman, Steven Fikes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 25, 2004
Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitisPaul G Ambrose, Jack B Anon, Joel S Owen, et al.
Pageof 16